Susan M. Jones, Ph.D.


Contact: 303-789-8951



My scientific career has led me to my current position as supervisor of the Neurotrauma Research Laboratory at Swedish Medical Center. Funded by a grant from Swedish Medical Center to J. P. Elliott M.D., the lab seeks to understand the mechanisms of neurotrauma-induced damage and potential neuroprotection. My interest in the neurobiology of disease has resulted in my research experience in the fields of epilepsy, Parkinson’s Disease, apoptosis and stroke. My background includes a large variety of experience, both in vivo and in vitro. In graduate school, I examined the role of NMDA receptors in amygdaloid kindling, a model of epilepsy. I went on to study the effects of anticonvulsants on ion channels, and the role of ion channels in the development of the nervous system. In keeping with my interest in the neurobiology of disease, I researched mechanisms of cell death related to animal models of Parkinson’s disease. Currently, we are examining the role of arginine vasopressin in stroke-induced injury.



Ph.D. in Neuroscience (1989, Univ. Texas Med Br.)

M.S. Biopsychology (1983, Syracuse University)

B.A. Psychology (1980, New Mexico State Univ.)


Postdoctoral Training:

Staff Fellow/National Research Council Associate (10/89-6/91); Neuronal Excitability Section, NIH/NINDS.

Postdoctoral Fellow (7/91-7/94), Univ. Colorado Health Sci. Ctr, Dept. Physiology



1. Zeynalov, E., Jones, S.M. Recent Advances and Future Directions in Preclinical Research of AVP Receptor Blocker Conivaptan in the Context of Stroke. Neural Regeneration Research, 11(3), Mar 2016.

2. Zeynalov, E., Jones, S.M, Elliott, J.P. Continuous IV Infusion is the Choice Treatment Route for Arginine-Vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-Evoked Brain Edema, Journal of Visualized Experiments, In Press 2016.

3. Zeynalov, E., Jones, S.M., Seo, J.W., Snell, L.D. and Elliott, J.P. Arginine-vasopressin receptor blocker Conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in mice. PLOS One, 10(8), e0136121, 2015.

4. Seo, J.W., Jones, S.M., Hostetter, T., Iliff, J. and West, G.A. Methamphetamine induces the release of endothelin. J. Neurosci. Res, 94:170-178, 2015.

5. Novak, A.E., Jones, S.M. and Elliott, J.P. HIF structural subunits are differentially regulated at the gene level after activation of the hypoxic pathway. In Preparation.

6. Jones, S.M., Novak, A.E., Elliott, J.P. The role of HIF in cobalt-induced ischemic tolerance. Neuroscience 252:420-430, 2013.

7. Jones, S.M., Novak, A.E., Elliott, J.P. Primary culture of cellular subtypes from postnatal mouse for in vitro studies of oxygen glucose deprivation. J. Neurosci. Methods. 199:241-248, 2011.

8. Zawada,W.M., Banninger, G.P., Thornton, J., Marriott, B., Cantu, D., Rachubinski, A.L., Das, M., Griffin, S.T. and Jones, S.M. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. Journal of Neuroinflammation 81:129, 2011.

9. Grammatopoulos, T.N., Jones, S.M., Yoshimura, M., Hoover, B.R., Das, M., Snyder, E.Y., Larson, G.A., Zahniser, N.R., Tabakoff, B., Zawada,W.M. Neurotransplantation of stem cells genetically modified to express human dopamine transporter reduces alcohol consumption. Stem Cell Res Ther. 1(5):36, 2010.

10. Ahmadi, F.A., Grammatopoulos, T.N., Poczobutt, A.M., Jones, S.M. Snell, L.D., Das, M. and Zawada, W.M. Dopamine selectively sensitizes dopaminergic neurons to rotenone-induced apoptosis. Neurochem. Res. 33(5): 886-901, 2008.

11. Grammatopoulos, T.N., Jones, S.M., Ahmadi, F.A., Hoover, B.R., Snell, L.D., Skoch, J., Jhaveri, V.V., Poczobutt, A.M., Weyhenmeyer, J.A. and Zawada, W.M. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Molecular Neurodegeneration, 2:1, 2007.

12. Grammatopoulos, T.N., Ahmadi, F., Jones, S.M., Fariss, M.W., Weyhenmeyer, J.A. and Zawada, W.M. Angiotensin II protects cultured midbrain dopaminergic neurons against rotenone-induced cell death.  Brain Research, 1045, 64-71, 2005.

13. Cavazos, J.E., Jones, S.M., and Cross, D. J. Sprouting and synaptic reorganization in the subiculum and CA1 region of the hippocampus in acute and chronic models of partial-onset epilepsy.  Neuroscience 126:677-688, 2004.

14. Ahmadi F.A., Linseman D.A., Grammatopoulos T.N., Jones S.M., Bouchard R.J., Freed C.R., Heidenreich K.A., Zawada W.M. The pesticide rotenone induces caspase-3-mediated apoptosis in ventral mesencephalic dopaminergic neurons.  J Neurochem. 87(4):914-21, 2003.

15. Jones, S.M., Hofmann, A.D., Lieber, J.L. and Ribera, A.B. Overexpression of potassium channel RNA rescues neurons from suppression of morphological differentiation in vitro.  Neurosci, 15:2867-2874, 1995.

16. Jones, S.M. and Ribera, A.B. Overexpression of a potassium channel gene perturbs neural differentiation. J. Neurosci. 14:2789-2799, 1994.

17. Johnson, K.M., Snell, L.D., Sacaan, A.I. and Jones, S.M. Pharmacologic regulation of the NMDA receptor-ionophore complex.  In Sigma, PCP and NMDA Receptors, ed. by E.B. De Souza, D. Clouet, and E.D. London, NIDA Res. Monograph Series, pp 13-40, 1993.

18. Jones, S.M. and Rogawski, M.A. The anticonvulsant (+)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10,-imine (ADCI) selectively blocks NMDA-activated current in cultured hippocampal neurons under voltage-clamp: kinetic analysis and comparison with MK-801. Mol. Neuropharmacol., 2:303-310, 1992.

19. Donevan, S.D., Jones, S.M. and Rogawski, M.A. Arcaine blocks N-methyl-D-aspartate receptor responses by an open channel mechanism: whole-cell and single-channel recording studies in cultured hippocampal neurons. Mol. Pharmacol.,41:727-735, 1992.

20. Rogawski, M.A., Yamaguchi, S-I., Blake, P.A., Jones, S.M., Bieda, M.C., de Costa, B.R. and Thurkauf, A. Anticonvulsant 1-phencycloalkylamine analogs: uncompetitive NMDA antagonists with low motor toxicity.  In Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection?, ed. by J.M. Kamenka and E.F. Domino, pp. 747-758, NPP Books, Ann Arbor, MI, 1992.

21. Rogawski, M.A., Yamaguchi, S-I., Jones, S.M., Thurkauff, A., Monn, J.A. and Rice, K.C. Anticonvulsant activity of the low affinity uncompetitive NMDA antagonist 5-aminocarbonyl-5H-dibenzo[a,d]cyclohepten-5,10-imine (ADCI):  Comparison with the structural analogs dizolcilpine (MK-801) and carbamazepine.  Pharmacol. Exp. Therap. 259:30-37, 1991.

22. Johnson, K.M. and Jones, S.M. Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential.  Rev. Pharmacol. Toxicol., 30:707-750, 1990.

23. Jones, S.M. and Johnson, K.M. Effects of amygdaloid kindling on NMDA receptor function and regulation.  Neurol., 106:52-60, 1989.

24. Jones, S.M., Snell, L.D. and Johnson, K.M. Characterization of the binding of radioligands to the N-methyl-D-aspartate, phencyclidine and glycine receptors in buffy coat membranes.  Pharmacol. Methods, 21:161-168, 1989.

25. Ferkany, J.W., Kyle, D.J., Willetts, J., Rzeszotarski, W.J., Guzewska, M.E., Ellenberger, S.R., Jones, S.M., Sacaan, A.I., Snell, L.D., Borosky, , Jones, B.E., Johnson, K.M., Balster, R.L., Burchett, K., Kawasaki, K., Hoch, D.B. and Dingledine, R. Pharmacological profile of NPC 12626, a novel, competitive N-methyl-D-aspartate receptor antagonist. J. Pharmacol. Exp. Therap. 250:100-109, 1989.

26. Johnson, K.M., Snell, L.D., Sacaan, A.I., and Jones, S.M. (1989) Pharmacological regulation of the phencyclidine-binding site associated with the N-methyl-D-aspartate receptor-operated ion channel. Drug Dev. Res. 17: 281-297.

27. Johnson, K.M., Snell, L.D., Jones, S.M., and Qi, H.Q.  Glycine antagonist activity of simple glycine analogues and N-methyl-D-aspartate receptor antagonists. In: Frontiers in Excitatory Amino Acid Research, edited by E.A. Cavalhiero, J. Lehmann and L. Turski. New York: Alan R. Liss, Inc., 1988, p. 551-558.

28. Jones, S.M., Snell, L.D., and Johnson, K.M. Phencyclidine selectively inhibits N-methyl-D-aspartate induced hippocampal 3H-NE release. In: Excitatory Amino Acid Transmission, edited by T. P. Hicks, D. Lodge and H. McLennan. New York: Alan R. Liss, Inc., 1987, p. 119-122.

29. Jones, S.M., Snell, L.D. and Johnson, K.M. Phencyclidine selectively inhibits N-methyl-D-aspartate-induced hippocampal [3H]norepinephrine release.  Pharmacol. Exp. Therap. 240:492-497, 1987.

30. Jones, S.M., Snell, L.D. and Johnson, K.M. Inhibition by phencyclidine of excitatory amino acid-stimulated release of neurotransmitter in the nucleus accumbens. 26:173-179, 1987.

31. Snell, L.D., Jones, S.M. and Johnson, K.M. Inhibition of N-methyl-D-aspartate-induced hippocampal [3H] norepinephrine release by phencyclidine is dependent on potassium concentration.  Lett. 78:333-337, 1987.

32. Scharoun, S.L., Barone, F.C., Wayner, M.J., Jones, S.M. Vagal and gastric connections to the central nervous system determined by the transport of horseradish peroxidase.  Brain Res. Bull., 13:573-583, 1984.

33. Adams, J. and Jones, S.M. Age differences in water maze performance and swimming behavior in the rat.  and Behav. 33:851-855, 1984.